We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Recommends Trial Designs for Unresponsive Non-Muscle Invasive Bladder Cancer
FDA Recommends Trial Designs for Unresponsive Non-Muscle Invasive Bladder Cancer
The FDA published recommendations for clinical trial designs for patients with bladder cancer, with separate considerations for patients with and without active disease. The agency’s draft guidance focuses on developing drugs and biologics for non-muscle invasive disease that has not responded to treatment with bacillus Calmette-Guerin immunotherapy.